Extendicare Inc.

EXE.TOTSXHealthcare● Active

$32.99

$-0.15(-0.45%)

Market Cap$3.1B

P/E Ratio—

52W High$35.62

52W Low$12.12

Avg Volume341K

Open$33.20

Beta1.16

Free Cash Flow Financials Revenue

Extendicare Inc. (EXE.TO) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

EXE.TO · free cash flow · updated Jun 8, 2026

Core FCF metrics

EXE.TO · FCF · TTM · margin & CAGR

Free cash flow was $63.4M for FY2025 (fiscal year ending 2025-12-31), down 37.7% year-over-year The FCF margin was 3.8%. Five-year CAGR stands at -6.4%.

FY2025 Free Cash Flow$63.4M▼ -37.7% YoY

Trailing 12M (TTM)$49.3Mtrailing 4 quarters sum

FCF Margin3.8%$63.4M ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGR-6.4%FY2020 → FY2025

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

EXE.TO · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest$165.2M(102M)$63.4M▼ 37.7%3.8%

FY2024$143.6M(42M)$101.7M▲ +195.8%6.9%

FY2023$23.3M(129M)−$106.1M▼ 3745.3%-8.1%

FY2022$98.9M(102M)−$2.8M▲ +54.7%-0.2%

FY2021$59.1M(65M)−$6.1M▼ 106.9%-0.5%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

EXE.TO · P/FCF · FCF yield · FCF per share

Extendicare Inc. (EXE.TO) trades at a FCF yield of 1.57% and a price-to-free-cash-flow ratio of 56.9x. FCF per share stands at $0.58, calculated using trailing twelve-month FCF divided by basic weighted-average shares outstanding.

FCF Yield (TTM)

1.57%

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

$0.58

TTM FCF ÷ Shares Outstanding

Price / FCF

x56.9

Share Price ÷ FCF per Share

EV / FCF (TTM)

x63.9

Enterprise Value basis

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

EXE.TO · cash flow statement · operating / investing / financing

For FY2025, Extendicare Inc. generated $165.2M in operating cash flow and spent 102M in capital expenditures, yielding $63.4M in free cash flow.

Operating Activities

+$165.2M

Cash from core business operations

2025-12-31

Investing Activities

−$119.0M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

+$180.4M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF ($165.2M) − |CapEx| (102M) = FCF ($63.4M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

EXE.TO vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Extendicare Inc.YOU

EXE.TO

$63.4M-37.7%3.8%

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Extendicare Inc. (EXE.TO) reported free cash flow of $63.4M for FY2025 (fiscal year ending 2025-12-31), down 37.7% year-over-year. The FCF margin was 3.8%.

Based on available data, Extendicare Inc. has maintained positive free cash flow for at least 10 fiscal year(s). FCF peaked at $101.7M in FY2024. The 5-year CAGR stands at -6.4%.

Extendicare Inc.'s FCF yield is 1.57% and price-to-FCF ratio is 56.9x for FY2025, based on the latest available data.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

EXE.TO free cash flow · 8 questions

Extendicare Inc. free cash flow was $63.4M for FY2025, down 37.7% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at $49.3M.

EXE.TO free cash flowEXE.TO FCFEXE.TO FCF 2025EXE.TO free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Extendicare Inc. · Extendicare Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026